Estee Lauder is reportedly moving toward excluding K-beauty brand Dr.Jart+ from any potential divestiture plans after reclassifying the brand as a key growth asset within its global portfolio.
According to multiple industry sources, Estee Lauder’s management recently conducted a review of its global brand portfolio and concluded that Dr.Jart+ possesses strong long-term growth potential. As a result, market speculation regarding a possible sale of the brand is gradually losing credibility.
Meanwhile, among the three brands that had initially been considered for a package sale, Too Faced and Smashbox have reportedly remained under review for potential divestiture, with related discussions continuing.
The renewed growth of the global K-beauty market has also drawn fresh attention to Dr.Jart+’s dermatology-based skincare expertise and premium brand positioning.
Industry observers suggest that Estee Lauder has begun viewing Dr.Jart+ not merely as a portfolio asset, but as a future growth engine capable of driving long-term value for the company.
Sources familiar with the matter indicate that during the sale review process, a significant gap emerged between Estee Lauder’s valuation expectations and the prices offered by prospective buyers. This valuation disparity reportedly led to a reassessment of Dr.Jart+’s strategic importance and became one of the key factors supporting a decision to retain the brand.
In addition, growing global interest in K-beauty over the past year is said to have reinforced the value of Dr.Jart+’s international distribution network and strong brand recognition, influencing the company’s internal decision-making process.
As global demand for K-beauty products continues to expand, Dr.Jart+ is increasingly regarded as one of the few skincare brands capable of pursuing growth simultaneously in both European and Asian markets. As a result, industry analysts expect Estee Lauder to further strengthen marketing investments and accelerate product development initiatives surrounding the brand.
A global investment banking source involved in the process stated, “Estee Lauder has recently shifted away from its original plan of exploring a combined sale of Too Faced, Smashbox, and Dr.Jart+, and is now moving toward separating Dr.Jart+ from that process. The focus of current discussions appears to be shifting toward brand development and long-term growth strategies.”
Industry experts also expect Estee Lauder to strengthen its position within the K-beauty sector through Dr.Jart+. Expectations are growing that the brand will evolve beyond a portfolio holding and establish itself as one of Estee Lauder’s next-generation growth drivers.
